Mandar Deepak Muzumdar

Mandar Deepak Muzumdar

Auto-generated profile, based on publicly available information

Mandar Deepak Muzumdar

Yale Cancer Biology Institute, Yale University , West Haven, CT 06516

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2007 in Genesis
Verified
Journal Article
Closed access
PDF file
MMMandar Deepak Muzumdar
Mandar Deepak Muzumdar
BTBosiljka Tasic
Bosiljka Tasic
KMKazunari Miyamichi
Kazunari Miyamichi
LLLing Li
Ling Li
LLLiqun Luo
Liqun Luo

1 September 2003 in Neuron
Verified
Journal Article
Closed access
RMRobert Machold
Robert Machold
SHShigemi Hayashi
Shigemi Hayashi
MRMichael Rutlin
Michael Rutlin
MMMandar D. Muzumdar
Mandar D. Muzumdar
SNSusana Vaz Nery
Susana Vaz Nery
GFGord Fishell
Gord Fishell

1 May 2005 in Cell
Verified
Journal Article
Closed access
HZHui Zong
Hui Zong
JEJ. Sebastian Espinosa
J. Sebastian Espinosa
HSHelen Hong Su
Helen Hong Su
MMMandar D. Muzumdar
Mandar D. Muzumdar
LLLiqun Luo
Liqun Luo

30 April 2013 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
LGLipika Goyal
Lipika Goyal
MMMandar D. Muzumdar
Mandar D. Muzumdar
AZAndrew X. Zhu
Andrew X. Zhu
Hepatocellular carcinoma (HCC) is a significant cause of cancer-related morbidity and mortality worldwide. Despite improvements in local therapies, including surgical resection, liver transplantation, and transarterial embolization, the prognosis remains poor for the majority of patients who develop recurrence or present with advanced disease. Systemic therapy with the tyrosine kinase inhibitor sorafenib represents a milestone in advanced HCC but provides a limited survival benefit. Ongoing efforts to study hepatocarcinogenesis have identified an important role for c-MET signaling in the promotion of tumor growth, angiogenesis, and metastasis. In this review, we summarize the preclinical data from human tissue, cell lines, and animal models that implicate c-MET in the pathogenesis of HCC. We also evaluate potential biomarkers that may estimate prognosis or predict response to c-MET inhibitors for more rational clinical trial design. Finally, we discuss the latest clinical trials of c-MET inhibitors in advanced HCC. Clin Cancer Res; 19(9); 2310–8. ©2013 AACR.

23 October 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
MMMandar Deepak Muzumdar
Mandar Deepak Muzumdar
PCPan-Yu Chen
Pan-Yu Chen
KDKimberly Judith Dorans
Kimberly Judith Dorans
KCKatherine Minjee Chung
Katherine Minjee Chung
ABArjun Bhutkar
Arjun Bhutkar
TJTyler Jacks
Tyler Jacks
Activating mutations in the proto-oncogene KRAS are a hallmark of pancreatic ductal adenocarcinoma (PDAC), an aggressive malignancy with few effective therapeutic options. Despite efforts to develop KRAS-targeted drugs, the absolute dependence of PDAC cells on KRAS remains incompletely understood. Here we model complete KRAS inhibition using CRISPR/Cas-mediated genome editing and demonstrate that KRAS is dispensable in a subset of human and mouse PDAC cells. Remarkably, nearly all KRAS deficient cells exhibit phosphoinositide 3-kinase (PI3K)-dependent mitogen-activated protein kinase (MAPK) signaling and induced sensitivity to PI3K inhibitors. Furthermore, comparison of gene expression profiles of PDAC cells retaining or lacking KRAS reveal a role of KRAS in the suppression of metastasis-related genes. Collectively, these data underscore the potential for PDAC resistance to even the very best KRAS inhibitors and provide insights into mechanisms of response and resistance to KRAS inhibition.

1 May 2020 in Cell
Verified
Journal Article
Closed access
KCKatherine Minjee Chung
Katherine Minjee Chung
JSJaffarguriqbal Singh
Jaffarguriqbal Singh
LLLauren Lawres
Lauren Lawres
KDKimberly Judith Dorans
Kimberly Judith Dorans
CGCathy Garcia
Cathy Garcia
MMMandar Deepak Muzumdar
Mandar Deepak Muzumdar